BioSpace News Archive

Lannett Company, Inc. (LCI) (“Lannett” or “the Company”) today announced that it received a written notice from the New York Stock Exchange (“NYSE”) dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company’s common stock from the NYSE.

CytoSorbents Corporation announces that its pivotal STAR-T randomized, controlled trial has enrolled 80 patients, achieving the second of three key enrollment milestones, and triggering a pre-specified Data and Safety Monitoring Board (DSMB) safety review.

Algernon Pharmaceuticals Inc. is reminding its shareholders of the details of its previously announced rights offering as well as the cut off date and time for the exercise of those rights.

UCB will showcase data from its expansive and innovative neurology portfolio at the 75th American Academy of Neurology (AAN) Annual Meeting, April 22-27, 2023.

Luxa Biotechnology today announced the company will provide an update on the progress of a Phase 1/2a clinical trial evaluating transplantation of RPESC-RPE-4W to treat dry age-related macular degeneration (AMD) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in New Orleans from April 23– 27, 2023.

Abata Therapeutics today announced the appointment of Leonard “Lenny” Dragone, M.D., Ph.D., as its new chief medical officer.

Anaconda Biomed today announced the appointment of a new board chairperson, and the naming of a new chief medical officer.

Blue Water Vaccines Inc. today announced the signing of an Asset Purchase Agreement (the “Agreement”) with Veru Inc. (“Veru”) for the purchase of ENTADFI®.

Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced that multiple abstracts featuring updates on the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—including new preclinical research on VRDN-003—will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2023), to be held April 23-27, 2023, in New Orleans, Louisiana.